JP2021515046A - ビタミンcカップリング白金錯体、その中間体、その製造方法、医薬組成物及び使用 - Google Patents
ビタミンcカップリング白金錯体、その中間体、その製造方法、医薬組成物及び使用 Download PDFInfo
- Publication number
- JP2021515046A JP2021515046A JP2020568589A JP2020568589A JP2021515046A JP 2021515046 A JP2021515046 A JP 2021515046A JP 2020568589 A JP2020568589 A JP 2020568589A JP 2020568589 A JP2020568589 A JP 2020568589A JP 2021515046 A JP2021515046 A JP 2021515046A
- Authority
- JP
- Japan
- Prior art keywords
- human
- reaction
- cancer
- cyclobutane
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 title claims abstract description 133
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 title claims abstract description 71
- 229910052697 platinum Inorganic materials 0.000 title claims abstract description 36
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 title claims abstract description 30
- 229930003268 Vitamin C Natural products 0.000 title claims abstract description 30
- 235000019154 vitamin C Nutrition 0.000 title claims abstract description 30
- 239000011718 vitamin C Substances 0.000 title claims abstract description 30
- 238000010168 coupling process Methods 0.000 title claims abstract description 19
- 238000005859 coupling reaction Methods 0.000 title claims abstract description 19
- 230000008878 coupling Effects 0.000 title claims abstract description 17
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 11
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 84
- 229910001868 water Inorganic materials 0.000 claims abstract description 64
- 239000000203 mixture Substances 0.000 claims abstract description 54
- 150000001875 compounds Chemical class 0.000 claims abstract description 21
- 239000003814 drug Substances 0.000 claims abstract description 20
- 239000002246 antineoplastic agent Substances 0.000 claims abstract description 8
- 238000006243 chemical reaction Methods 0.000 claims description 249
- 239000011734 sodium Substances 0.000 claims description 56
- -1 alkyl primary amines Chemical class 0.000 claims description 41
- 210000004027 cell Anatomy 0.000 claims description 38
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 16
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 16
- 230000003287 optical effect Effects 0.000 claims description 14
- 239000012453 solvate Substances 0.000 claims description 14
- 229910052739 hydrogen Inorganic materials 0.000 claims description 13
- 150000003839 salts Chemical class 0.000 claims description 13
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 claims description 12
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical group [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 12
- 229910052751 metal Chemical group 0.000 claims description 12
- 239000002184 metal Chemical group 0.000 claims description 12
- 206010028980 Neoplasm Diseases 0.000 claims description 11
- 239000007864 aqueous solution Substances 0.000 claims description 11
- 150000007529 inorganic bases Chemical class 0.000 claims description 10
- 210000004881 tumor cell Anatomy 0.000 claims description 10
- 125000000217 alkyl group Chemical group 0.000 claims description 9
- 125000004429 atom Chemical group 0.000 claims description 9
- 125000002950 monocyclic group Chemical group 0.000 claims description 9
- 230000000737 periodic effect Effects 0.000 claims description 8
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 8
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 8
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 8
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 8
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 6
- 125000002947 alkylene group Chemical group 0.000 claims description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 6
- 201000007270 liver cancer Diseases 0.000 claims description 6
- 208000014018 liver neoplasm Diseases 0.000 claims description 6
- 125000000467 secondary amino group Chemical class [H]N([*:1])[*:2] 0.000 claims description 6
- 229910052717 sulfur Inorganic materials 0.000 claims description 6
- 239000011593 sulfur Substances 0.000 claims description 6
- 229910052708 sodium Inorganic materials 0.000 claims description 5
- 206010005003 Bladder cancer Diseases 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 4
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 4
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 4
- 206010033128 Ovarian cancer Diseases 0.000 claims description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 4
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 4
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 4
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 4
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 4
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 201000010881 cervical cancer Diseases 0.000 claims description 4
- 208000029742 colonic neoplasm Diseases 0.000 claims description 4
- 201000004101 esophageal cancer Diseases 0.000 claims description 4
- 206010017758 gastric cancer Diseases 0.000 claims description 4
- 201000001441 melanoma Diseases 0.000 claims description 4
- 229910052700 potassium Inorganic materials 0.000 claims description 4
- 201000011549 stomach cancer Diseases 0.000 claims description 4
- 201000002510 thyroid cancer Diseases 0.000 claims description 4
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 4
- MFGOFGRYDNHJTA-UHFFFAOYSA-N 2-amino-1-(2-fluorophenyl)ethanol Chemical compound NCC(O)C1=CC=CC=C1F MFGOFGRYDNHJTA-UHFFFAOYSA-N 0.000 claims description 3
- 206010025323 Lymphomas Diseases 0.000 claims description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- 125000003118 aryl group Chemical group 0.000 claims description 3
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 claims description 3
- HUCVOHYBFXVBRW-UHFFFAOYSA-M caesium hydroxide Inorganic materials [OH-].[Cs+] HUCVOHYBFXVBRW-UHFFFAOYSA-M 0.000 claims description 3
- 239000003446 ligand Substances 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 3
- 206010005949 Bone cancer Diseases 0.000 claims description 2
- 208000018084 Bone neoplasm Diseases 0.000 claims description 2
- 206010023774 Large cell lung cancer Diseases 0.000 claims description 2
- 206010024305 Leukaemia monocytic Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 208000003445 Mouth Neoplasms Diseases 0.000 claims description 2
- 125000005587 carbonate group Chemical group 0.000 claims description 2
- 201000010536 head and neck cancer Diseases 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 201000009546 lung large cell carcinoma Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 201000005831 male reproductive organ cancer Diseases 0.000 claims description 2
- 201000006894 monocytic leukemia Diseases 0.000 claims description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N nitrate group Chemical group [N+](=O)([O-])[O-] NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 2
- 208000031223 plasma cell leukemia Diseases 0.000 claims description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 2
- 229940088594 vitamin Drugs 0.000 claims description 2
- 229930003231 vitamin Natural products 0.000 claims description 2
- 235000013343 vitamin Nutrition 0.000 claims description 2
- 239000011782 vitamin Substances 0.000 claims description 2
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 2
- DRSHXJFUUPIBHX-UHFFFAOYSA-N COc1ccc(cc1)N1N=CC2C=NC(Nc3cc(OC)c(OC)c(OCCCN4CCN(C)CC4)c3)=NC12 Chemical compound COc1ccc(cc1)N1N=CC2C=NC(Nc3cc(OC)c(OC)c(OCCCN4CCN(C)CC4)c3)=NC12 DRSHXJFUUPIBHX-UHFFFAOYSA-N 0.000 claims 1
- 229910052788 barium Inorganic materials 0.000 claims 1
- IUJRHPSJWLCXAY-UHFFFAOYSA-N cyclobutane-1,1-dicarboxylic acid;platinum Chemical compound [Pt].OC(=O)C1(C(O)=O)CCC1 IUJRHPSJWLCXAY-UHFFFAOYSA-N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 19
- 230000000259 anti-tumor effect Effects 0.000 abstract description 4
- 230000000694 effects Effects 0.000 abstract description 4
- 238000009472 formulation Methods 0.000 abstract description 3
- 239000000126 substance Substances 0.000 abstract description 3
- 230000029142 excretion Effects 0.000 abstract description 2
- 210000003734 kidney Anatomy 0.000 abstract description 2
- 206010029155 Nephropathy toxic Diseases 0.000 abstract 1
- 238000010586 diagram Methods 0.000 abstract 1
- 230000007694 nephrotoxicity Effects 0.000 abstract 1
- 231100000417 nephrotoxicity Toxicity 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 154
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 90
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 81
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 75
- 229960005070 ascorbic acid Drugs 0.000 description 73
- 238000002360 preparation method Methods 0.000 description 64
- 239000002211 L-ascorbic acid Substances 0.000 description 46
- 235000000069 L-ascorbic acid Nutrition 0.000 description 38
- RQPZNWPYLFFXCP-UHFFFAOYSA-L barium dihydroxide Chemical compound [OH-].[OH-].[Ba+2] RQPZNWPYLFFXCP-UHFFFAOYSA-L 0.000 description 38
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 33
- 239000012043 crude product Substances 0.000 description 33
- 239000003921 oil Substances 0.000 description 31
- 229910001873 dinitrogen Inorganic materials 0.000 description 30
- 229910052757 nitrogen Inorganic materials 0.000 description 30
- 229910001863 barium hydroxide Inorganic materials 0.000 description 28
- 239000000047 product Substances 0.000 description 28
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical group [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 27
- 239000011668 ascorbic acid Substances 0.000 description 27
- CCQPAEQGAVNNIA-UHFFFAOYSA-N cyclobutane-1,1-dicarboxylic acid Chemical compound OC(=O)C1(C(O)=O)CCC1 CCQPAEQGAVNNIA-UHFFFAOYSA-N 0.000 description 27
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 26
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 26
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- 238000000034 method Methods 0.000 description 22
- 239000007787 solid Substances 0.000 description 22
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 21
- 239000002244 precipitate Substances 0.000 description 21
- 238000010898 silica gel chromatography Methods 0.000 description 19
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 18
- UMWYYMCOBYVEPY-UHFFFAOYSA-N azanide;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2] UMWYYMCOBYVEPY-UHFFFAOYSA-N 0.000 description 18
- 239000012467 final product Substances 0.000 description 18
- 238000004128 high performance liquid chromatography Methods 0.000 description 18
- 238000002953 preparative HPLC Methods 0.000 description 18
- 239000006228 supernatant Substances 0.000 description 18
- 239000012047 saturated solution Substances 0.000 description 16
- 239000002904 solvent Substances 0.000 description 16
- 239000003208 petroleum Substances 0.000 description 15
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 14
- 239000012074 organic phase Substances 0.000 description 14
- 239000000706 filtrate Substances 0.000 description 13
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 12
- HHCHFPCHBZIFPY-UHFFFAOYSA-L cyclohexane-1,1-diamine;platinum(2+);sulfate Chemical compound [Pt+2].[O-]S([O-])(=O)=O.NC1(N)CCCCC1 HHCHFPCHBZIFPY-UHFFFAOYSA-L 0.000 description 12
- 239000007788 liquid Substances 0.000 description 12
- 238000000746 purification Methods 0.000 description 12
- 238000000967 suction filtration Methods 0.000 description 12
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 11
- 239000012153 distilled water Substances 0.000 description 10
- 239000001257 hydrogen Substances 0.000 description 9
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 9
- HRGDZIGMBDGFTC-UHFFFAOYSA-N platinum(2+) Chemical compound [Pt+2] HRGDZIGMBDGFTC-UHFFFAOYSA-N 0.000 description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 8
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 8
- 0 CC(C)(OC1)O[C@@]1[C@](C)(C(OCCCC(C1)CC1(C(*)=O)C(OC(C)=O)=O)=C1OC)OC1=O Chemical compound CC(C)(OC1)O[C@@]1[C@](C)(C(OCCCC(C1)CC1(C(*)=O)C(OC(C)=O)=O)=C1OC)OC1=O 0.000 description 7
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 7
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 235000019270 ammonium chloride Nutrition 0.000 description 6
- 150000004985 diamines Chemical class 0.000 description 6
- 229920006395 saturated elastomer Polymers 0.000 description 6
- HJUGFYREWKUQJT-UHFFFAOYSA-N tetrabromomethane Chemical compound BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 description 6
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 6
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 5
- 239000012312 sodium hydride Substances 0.000 description 5
- 229910000104 sodium hydride Inorganic materials 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- OWOCGQANDMJCDN-UHFFFAOYSA-N 3-methylidenecyclobutane-1,1-dicarboxylic acid Chemical compound OC(=O)C1(CC(=C)C1)C(O)=O OWOCGQANDMJCDN-UHFFFAOYSA-N 0.000 description 4
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 230000003833 cell viability Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000010511 deprotection reaction Methods 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- XYVIKUTYMMOQFT-UHFFFAOYSA-N 2,2-ditert-butylpropanedioic acid Chemical compound CC(C)(C)C(C(O)=O)(C(O)=O)C(C)(C)C XYVIKUTYMMOQFT-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical group CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- HECRSPSGIATUHP-UHFFFAOYSA-N CC(C)(C)C(C(CBr)C1C(C)(C)C)C1(C(O)=O)C(O)=O Chemical compound CC(C)(C)C(C(CBr)C1C(C)(C)C)C1(C(O)=O)C(O)=O HECRSPSGIATUHP-UHFFFAOYSA-N 0.000 description 3
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 229910002091 carbon monoxide Inorganic materials 0.000 description 3
- YAYRGNWWLMLWJE-UHFFFAOYSA-L carboplatin Chemical compound O=C1O[Pt](N)(N)OC(=O)C11CCC1 YAYRGNWWLMLWJE-UHFFFAOYSA-L 0.000 description 3
- 229960004562 carboplatin Drugs 0.000 description 3
- 230000003197 catalytic effect Effects 0.000 description 3
- 229960004316 cisplatin Drugs 0.000 description 3
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 3
- 229960001756 oxaliplatin Drugs 0.000 description 3
- 239000007800 oxidant agent Substances 0.000 description 3
- 230000001590 oxidative effect Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000012265 solid product Substances 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- 150000003700 vitamin C derivatives Chemical class 0.000 description 3
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 2
- LZDKZFUFMNSQCJ-UHFFFAOYSA-N 1,2-diethoxyethane Chemical compound CCOCCOCC LZDKZFUFMNSQCJ-UHFFFAOYSA-N 0.000 description 2
- LTMRRSWNXVJMBA-UHFFFAOYSA-L 2,2-diethylpropanedioate Chemical compound CCC(CC)(C([O-])=O)C([O-])=O LTMRRSWNXVJMBA-UHFFFAOYSA-L 0.000 description 2
- YHDMBRSCWYVZPG-UHFFFAOYSA-N CC(C)(C)C(C(CCBr)C1C(C)(C)C)C1(C(O)=O)C(O)=O Chemical compound CC(C)(C)C(C(CCBr)C1C(C)(C)C)C1(C(O)=O)C(O)=O YHDMBRSCWYVZPG-UHFFFAOYSA-N 0.000 description 2
- SQOSYKKUKADLRG-UHFFFAOYSA-N CC(C)(C)C(C(CCO)C1C(C)(C)C)C1(C(O)=O)C(O)=O Chemical compound CC(C)(C)C(C(CCO)C1C(C)(C)C)C1(C(O)=O)C(O)=O SQOSYKKUKADLRG-UHFFFAOYSA-N 0.000 description 2
- IZVPORRYCLVKCT-UHFFFAOYSA-N CC(C)(C)C(C1)C(CCCBr)(C(C)(C)C)C1(C(O)=O)C(O)=O Chemical compound CC(C)(C)C(C1)C(CCCBr)(C(C)(C)C)C1(C(O)=O)C(O)=O IZVPORRYCLVKCT-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 230000029936 alkylation Effects 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- QVQLCTNNEUAWMS-UHFFFAOYSA-N barium oxide Chemical compound [Ba]=O QVQLCTNNEUAWMS-UHFFFAOYSA-N 0.000 description 2
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 2
- 229910000024 caesium carbonate Inorganic materials 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 229940117975 chromium trioxide Drugs 0.000 description 2
- WGLPBDUCMAPZCE-UHFFFAOYSA-N chromium trioxide Inorganic materials O=[Cr](=O)=O WGLPBDUCMAPZCE-UHFFFAOYSA-N 0.000 description 2
- GAMDZJFZMJECOS-UHFFFAOYSA-N chromium(6+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[Cr+6] GAMDZJFZMJECOS-UHFFFAOYSA-N 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- IBHFYWJICITPEM-UHFFFAOYSA-N ditert-butyl 2-(3-hydroxypropyl)cyclobutane-1,1-dicarboxylate Chemical compound CC(C)(C)OC(=O)C1(CCC1CCCO)C(=O)OC(C)(C)C IBHFYWJICITPEM-UHFFFAOYSA-N 0.000 description 2
- QWAMSMRVBSGIAB-UHFFFAOYSA-N ditert-butyl 3-(hydroxymethyl)cyclobutane-1,1-dicarboxylate Chemical compound CC(C)(C)OC(=O)C1(CC(C1)CO)C(=O)OC(C)(C)C QWAMSMRVBSGIAB-UHFFFAOYSA-N 0.000 description 2
- CLPHAYNBNTVRDI-UHFFFAOYSA-N ditert-butyl propanedioate Chemical compound CC(C)(C)OC(=O)CC(=O)OC(C)(C)C CLPHAYNBNTVRDI-UHFFFAOYSA-N 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000003456 ion exchange resin Substances 0.000 description 2
- 229920003303 ion-exchange polymer Polymers 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 150000003057 platinum Chemical class 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 229910021642 ultra pure water Inorganic materials 0.000 description 2
- 239000012498 ultrapure water Substances 0.000 description 2
- GVSOIHLBHAKZIV-UHFFFAOYSA-N 2-benzhydrylpropanedioic acid Chemical compound C=1C=CC=CC=1C(C(C(=O)O)C(O)=O)C1=CC=CC=C1 GVSOIHLBHAKZIV-UHFFFAOYSA-N 0.000 description 1
- YIYBIXRNBQUUEB-UHFFFAOYSA-N 3,5-dibromopentoxymethylbenzene Chemical compound C1=CC=C(C=C1)COCCC(CCBr)Br YIYBIXRNBQUUEB-UHFFFAOYSA-N 0.000 description 1
- AJLYOHLKYFSFSE-UHFFFAOYSA-N 3-benzhydryloxy-3-oxopropanoic acid Chemical compound C=1C=CC=CC=1C(OC(=O)CC(=O)O)C1=CC=CC=C1 AJLYOHLKYFSFSE-UHFFFAOYSA-N 0.000 description 1
- WJEWJUSEMHYOAQ-UHFFFAOYSA-N 4,6-dibromohexan-2-yloxymethylbenzene Chemical compound CC(CC(CCBr)Br)OCC1=CC=CC=C1 WJEWJUSEMHYOAQ-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- FMNRSJILSHVOPC-UHFFFAOYSA-N C1C(CC1(C(=O)O)C(=O)O)CCBr Chemical compound C1C(CC1(C(=O)O)C(=O)O)CCBr FMNRSJILSHVOPC-UHFFFAOYSA-N 0.000 description 1
- KEIXSOCNEOIXQS-UHFFFAOYSA-N CC(C)(C)C(C(CO)C1C(C)(C)C)C1(C(O)=O)C(O)=O Chemical compound CC(C)(C)C(C(CO)C1C(C)(C)C)C1(C(O)=O)C(O)=O KEIXSOCNEOIXQS-UHFFFAOYSA-N 0.000 description 1
- GRWVHEUNUITIRB-UHFFFAOYSA-N CC(C)(C)C(C(COCC1=CC=CC=C1)C1C(C)(C)C)C1(C(O)=O)C(O)=O Chemical compound CC(C)(C)C(C(COCC1=CC=CC=C1)C1C(C)(C)C)C1(C(O)=O)C(O)=O GRWVHEUNUITIRB-UHFFFAOYSA-N 0.000 description 1
- RNDUAMJHFUMRHV-UHFFFAOYSA-N CC(C)(C)C(C1)C(CCCO)(C(C)(C)C)C1(C(O)=O)C(O)=O Chemical compound CC(C)(C)C(C1)C(CCCO)(C(C)(C)C)C1(C(O)=O)C(O)=O RNDUAMJHFUMRHV-UHFFFAOYSA-N 0.000 description 1
- WFERCYXCXLJEAO-UHFFFAOYSA-N CC(C)(C)C(C1)C(CCCOCC2=CC=CC=C2)(C(C)(C)C)C1(C(O)=O)C(O)=O Chemical compound CC(C)(C)C(C1)C(CCCOCC2=CC=CC=C2)(C(C)(C)C)C1(C(O)=O)C(O)=O WFERCYXCXLJEAO-UHFFFAOYSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 1
- WISMPHXMMNTECE-VCZPFQCISA-N N[C@H](CCCC1)[C@@H]1NP(OC(C12CC(COC([C@@H]([C@H](CO)O)OC3=O)=C3O)C1)=O)OC2=O Chemical compound N[C@H](CCCC1)[C@@H]1NP(OC(C12CC(COC([C@@H]([C@H](CO)O)OC3=O)=C3O)C1)=O)OC2=O WISMPHXMMNTECE-VCZPFQCISA-N 0.000 description 1
- BBUKJXPSFMCTII-QPUJVOFHSA-N OC[C@@H]([C@H](C(O)=C1OCC(CCC(O)=O)CCC(O)=O)OC1=O)O Chemical compound OC[C@@H]([C@H](C(O)=C1OCC(CCC(O)=O)CCC(O)=O)OC1=O)O BBUKJXPSFMCTII-QPUJVOFHSA-N 0.000 description 1
- WAFIDOXOZMBEFD-IONNQARKSA-N OC[C@@H]([C@H](C(O)=C1OCCC(C2)CC2(C(O)=O)C(O)=O)OC1=O)O Chemical compound OC[C@@H]([C@H](C(O)=C1OCCC(C2)CC2(C(O)=O)C(O)=O)OC1=O)O WAFIDOXOZMBEFD-IONNQARKSA-N 0.000 description 1
- JFWPYVAUZVUOQM-WCBMZHEXSA-N OC[C@@H]([C@H](C(OCCCC(C1)CC1(C(O)=O)C(O)=O)=C1O)OC1=O)O Chemical compound OC[C@@H]([C@H](C(OCCCC(C1)CC1(C(O)=O)C(O)=O)=C1O)OC1=O)O JFWPYVAUZVUOQM-WCBMZHEXSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical group [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- MNRIGUQUGLJEOQ-UHFFFAOYSA-N [3-bromo-2-(bromomethyl)propoxy]methylbenzene Chemical compound BrCC(CBr)COCC1=CC=CC=C1 MNRIGUQUGLJEOQ-UHFFFAOYSA-N 0.000 description 1
- GPWHDDKQSYOYBF-UHFFFAOYSA-N ac1l2u0q Chemical compound Br[Br-]Br GPWHDDKQSYOYBF-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 159000000009 barium salts Chemical class 0.000 description 1
- TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical group [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- BEPAFCGSDWSTEL-UHFFFAOYSA-N dimethyl malonate Chemical compound COC(=O)CC(=O)OC BEPAFCGSDWSTEL-UHFFFAOYSA-N 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- NINWKOHSLUEYIF-UHFFFAOYSA-N ditert-butyl 2-(3-phenylmethoxypropyl)cyclobutane-1,1-dicarboxylate Chemical compound CC(C)(C)OC(=O)C1(CCC1CCCOCC2=CC=CC=C2)C(=O)OC(C)(C)C NINWKOHSLUEYIF-UHFFFAOYSA-N 0.000 description 1
- LLCYQNPKSSHBJZ-UHFFFAOYSA-N ditert-butyl 3-(2-hydroxyethyl)cyclobutane-1,1-dicarboxylate Chemical compound CC(C)(C)OC(=O)C1(CC(C1)CCO)C(=O)OC(C)(C)C LLCYQNPKSSHBJZ-UHFFFAOYSA-N 0.000 description 1
- FEFMPNKROUCSJH-UHFFFAOYSA-N ditert-butyl 3-(2-phenylmethoxyethyl)cyclobutane-1,1-dicarboxylate Chemical compound CC(C)(C)OC(=O)C1(CC(C1)CCOCC2=CC=CC=C2)C(=O)OC(C)(C)C FEFMPNKROUCSJH-UHFFFAOYSA-N 0.000 description 1
- MCRSLNWSEUNRJC-UHFFFAOYSA-N ditert-butyl 3-(phenylmethoxymethyl)cyclobutane-1,1-dicarboxylate Chemical compound CC(C)(C)OC(=O)C1(CC(C1)COCC2=CC=CC=C2)C(=O)OC(C)(C)C MCRSLNWSEUNRJC-UHFFFAOYSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 230000009422 growth inhibiting effect Effects 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 150000002641 lithium Chemical group 0.000 description 1
- 208000016848 malignant germ cell tumor Diseases 0.000 description 1
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
- 230000003589 nefrotoxic effect Effects 0.000 description 1
- 231100000381 nephrotoxic Toxicity 0.000 description 1
- 239000000820 nonprescription drug Substances 0.000 description 1
- 150000002902 organometallic compounds Chemical class 0.000 description 1
- BSCHIACBONPEOB-UHFFFAOYSA-N oxolane;hydrate Chemical compound O.C1CCOC1 BSCHIACBONPEOB-UHFFFAOYSA-N 0.000 description 1
- PQTLYDQECILMMB-UHFFFAOYSA-L platinum(2+);sulfate Chemical compound [Pt+2].[O-]S([O-])(=O)=O PQTLYDQECILMMB-UHFFFAOYSA-L 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- PXWLVJLKJGVOKE-UHFFFAOYSA-N propyphenazone Chemical compound O=C1C(C(C)C)=C(C)N(C)N1C1=CC=CC=C1 PXWLVJLKJGVOKE-UHFFFAOYSA-N 0.000 description 1
- 229960002189 propyphenazone Drugs 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229910001961 silver nitrate Inorganic materials 0.000 description 1
- YPNVIBVEFVRZPJ-UHFFFAOYSA-L silver sulfate Chemical compound [Ag+].[Ag+].[O-]S([O-])(=O)=O YPNVIBVEFVRZPJ-UHFFFAOYSA-L 0.000 description 1
- 229910000367 silver sulfate Inorganic materials 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 125000004436 sodium atom Chemical group 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000005292 vacuum distillation Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
- C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
- C07F15/0086—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/62—Three oxygen atoms, e.g. ascorbic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
- C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
- C07F15/0086—Platinum compounds
- C07F15/0093—Platinum compounds without a metal-carbon linkage
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Catalysts (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Furan Compounds (AREA)
Abstract
Description
n=0、1、2、3、4、5又は6である(選択的に、n=0、1、2又は3である)。
各Mはそれぞれ独立して、水素原子、又は周期表第IA族の金属原子を表し、或いは、2つのMは一体となって、周期表の第IIA族の金属原子を表し、選択的に、Mはそれぞれ独立して、H、Na、K、Li、Csを表し、或いは、2つのMは一体となってBaを表し、
n=0、1、2、3、4、5又は6であり(選択的に、n=0、1、2又は3である)、
mは、0又は1であり、
Rは、
式(II)中:
X及びYは配位子であり、前記X及びYはそれぞれ独立して、NH3、C1−C8直鎖又は分岐アルキル1級アミン(選択的に、C1−C6の直鎖又は分岐アルキル1級アミンであり、選択的に、C1−C3の直鎖又は分岐アルキル1級アミンである)、C3−C8環状アルキル1級アミン(選択的に、C3−C6環状アルキル1級アミンである)、芳香族1級アミン、1個又は複数個のC1−C4アルキル置換の芳香族1級アミン、分子式がR1−NH−R2の2級アミンから選択される。そのうち、R1及びR2はそれぞれ独立して、C1−C8の直鎖又は分岐アルキル基(選択的に、C1−C6の直鎖又は分岐アルキル基であり、選択的に、C1−C3の直鎖又は分岐アルキル基である)を表し、或いは、R1−NH−R2は一体となって、C4−C8の脂環式2級アミン(C5−C6の脂環式2級アミンであっても良い)、含窒素芳香族複素環化合物、1個又は複数個のC1−C4直鎖又は分岐アルキル置換の含窒素芳香族複素環化合物、含硫黄芳香族複素環化合物、又は含硫黄非芳香族複素環化合物を形成している。ただし、前記「芳香族1級アミン」におけるアリール基は、5〜10員の単環又は縮合二環式芳香族基であり、前記「芳香族複素環」は、5〜10員の単環又は縮合二環式複素芳香環であり、前記「非芳香族複素環」は、4〜10員の単環又は多環脂肪族複素環である。
A1及びA2は同一でも異なっていてもよく、それぞれ独立して、ヒドロキシル基、ニトレート基、又はパークロレート基を表し、或いは、A1及びA2は共に、サルフェート基、又はカーボネート基を表す。
式(III)中:
各Mはそれぞれ独立して、水素原子、又は周期表第IA族の金属原子を表し、或いは、2つのMは一体となって、周期表の第IIA族の金属原子を表し、選択的に、Mはそれぞれ独立して、H、Na、K、Li、Csを表し、或いは、2つのMは一体となってBaを表し、
n=0、1、2、3、4、5又は6であり(選択的に、n=0、1、2又は3である)、
mは、0又は1であり、
Rは、
MS(m/z):582.0 [M + Na]+
(3)3−ブロモプロピル−シクロブタン−1,1−ジカルボン酸ジ−t−ブチルの調製
(4)5,6−O−イソプロピリデン−2−O−(3−プロピレン−シクロブタン−1,1−ジカルボン酸ジ−t−ブチル)−3−O−ベンジル−L−アスコルビン酸の調製
2−O−(3−プロピレン−シクロブタン−1,1−ジカルボン酸)L−アスコルビン酸の粗製品(1.0g)を、10mLの水に溶解させて、飽和水酸化バリウム溶液を加えて反応液のpHを7に調整し、室温で30分撹拌した。窒素の保護下で、ジアミン硫酸白金(1.0g)を、2mlの水に溶解させて、上記反応液に加えて、水酸化バリウム溶液でpHを7に調整し、室温で遮光して3時間撹拌した。HPLCで反応をモニタリングし、反応終了後、遠心機を用いて沈殿物を除去し、上澄みを収集し、セミ分取高圧液体クロマトグラフィーで分離して凍結乾燥機を用いて凍結乾燥し、0.9gの最終製品を得て、白色固体であった。
MS(m/z):676.1 [M + Na]+
MS(m/z):676.1 [M + Na]+
実験方法:5mlのEPチューブで約0.5mlの蒸留水を取り、溶解できなくなる(25℃で超音波振とうしても、濁りが生じる)まで、乾燥の化合物をゆっくり加えた。溶液を別の5mLの清潔で秤量済みのEPチューブにろ取し、再度秤量し、溶液の重量を算出する。ろ液を凍結乾燥し、秤量し残留固形分の溶質の質量を算出すれば、溶媒の重量と溶質の質量を把握でき、これによって、化合物の水への溶解度を算出できる。
以下の実験は、本発明の腫瘍治療のためのビタミンCカップリング白金錯体の、異なる種類のヒト腫瘍細胞に対する増殖阻害効果について、実験検証を行った。
細胞培養液:
10%ウシ胎児血清(fetal bovine serum)を含む細胞培養液を用いる。
HERAcell150i型二酸化炭素インキュベーター(Thermo社)、研究グレードの倒立蛍光顕微鏡(ニコン社、日本)、多機能マイクロプレートリーダー(Thermo社)、超低温冷蔵庫(Thermo)、生物学的安全キャビネット(1300 Series A2、Thermo社)、マイクロピペット(独eppendorf社)、超純水システム(米Milli−Q社)。
細胞毒性実験では、MTT法を用いて試験を行った。対数期の腫瘍細胞を集めて、細胞懸濁液の濃度を調整して、穴ごとに100μlを加えて、被測定細胞の密度を1000〜10000個/穴に調整して培養プレートに接種した(エッジ穴を無菌PBSで充填した)。5%CO2、37℃で、細胞が接着するまで(96穴平底プレート)インキュベートし、異なる濃度勾配の薬物を、穴ごとに100μl加えて、各穴の平行穴を4個設けた。5%CO2、37℃の条件で72時間インキュベートし、倒立顕微鏡で観察した。96穴板プレートに、調製されたMTT溶液(5mg/ml)を、穴ごとに20μl加えて、均一に混合し、37℃、5%CO2の条件で4hインキュベートした後、プレート内の液体を捨て、穴ごとに150μlのDMSOを加えて、マイクロプレートリーダーで3分間振とうし、490nmでOD値(光学濃度値)を測定した。
上記同様の条件で、被測定活性成分を添加せず、最終的に腫瘍細胞の490nmで測定されたOD値を得た。
細胞阻害率の算出:下記の式によって薬物の腫瘍細胞増殖に対する阻害率を算出した。
2)各薬物濃度での細胞生存率を求めて、薬物濃度に対してプロットした。これをもって、異なる薬物濃度の腫瘍細胞増殖に対する阻害の効果を判断した。
3)細胞生存率が対照組の50%である場合の対応する薬物濃度は、薬物の腫瘍細胞に対する半数阻害濃度、すなわち、薬物のIC50値である。
Claims (10)
- 式(I)で示されるビタミンCカップリング白金錯体、又はその光学異性体、又はその薬学的に許容される塩、又はその溶媒和物。
或いは、X及びYは一体となって、式(IV)の構造を構成している。
n=0、1、2、3、4、5又は6である(選択的に、n=0、1、2又は3である)。
mは、0又は1である。
Rは、
- 前記X及びYはそれぞれ、NH3であり、或いは、X、Yは一体となって、トランス−(1R,2R)−シクロヘキサンジアミン、トランス−(1S,2S)−シクロヘキサンジアミン、シス−(1R,2S)−シクロヘキサンジアミン、シス−(1S,2R)−シクロヘキサンジアミン、ラセミトランス−1,2−シクロヘキサンジアミン、又はラセミシス−1,2−シクロヘキサンジアミンを形成していることを特徴とする請求項1に記載のビタミンCカップリング白金錯体、又はその光学異性体、又はその薬学的に許容される塩、又はその溶媒和物。
- 前記X及びYはそれぞれ、NH3であり、或いは、X、Yは一体となって、トランス−(1R,2R)−シクロヘキサンジアミンを形成していることを特徴とする請求項2に記載のビタミンCカップリング白金錯体、又はその光学異性体、又はその薬学的に許容される塩、又はその溶媒和物。
- 請求項1〜4のいずれか1項に記載のビタミンCカップリング白金錯体、又はその光学異性体、又はその薬学的に許容される塩、又はその溶媒和物の製造方法であって、式(II)化合物及び式(III)化合物に水を加えて水溶液として調製して反応させる工程を含み、反応水溶液に塩基を加えてpHを7〜9に調整してもよく、
選択的に、前記塩基は、無機塩基であり、選択的に、前記無機塩基は、水酸化ナトリウム、水酸化カリウム、炭酸ナトリウム、炭酸水素ナトリウム、炭酸カリウム、水酸化リチウム、水酸化セシウム又は水酸化バリウムから選択される1種又は複数種であり、
前記(II)の構造式は、
X及びYの定義は、式(I)と同様であり、
A1及びA2は同一でも異なっていてもよく、それぞれ独立して、ヒドロキシル基、ニトレート基又はパークロレート基を表し、或いは、A1及びA2は共に、サルフェート基、又はカーボネート基を表す。]
であり、
前記(III)の構造式は、
各Mはそれぞれ独立して、水素原子、又は周期表第IA族の金属原子を表し、或いは、2つのMは一体となって、周期表の第IIA族の金属原子を表し、選択的に、Mはそれぞれ独立して、H、Na、K、Li、Csを表し、或いは、2つのMは一体となってBaを表し、
n=0、1、2、3、4、5又は6(選択的に、n=0、1、2又は3である)、
mは、0又は1であり、
Rは、
であることを特徴とするビタミンCカップリング白金錯体、又はその光学異性体、又はその薬学的に許容される塩、溶媒化物の製造方法。 - 請求項1〜4のいずれか1項に記載のビタミンCカップリング白金錯体、又はその光学異性体、又はその薬学的に許容される塩、又はその溶媒和物の1種又は複数種、及び任意の薬学的に許容される担体を含む医薬組成物。
- 請求項1〜4のいずれか1項に記載のビタミンCカップリング白金錯体、又はその光学異性体、又はその薬学的に許容される塩、又はその溶媒和物、又は請求項7に記載の医薬組成物の、抗腫瘍薬を製造するための使用。
- 前記腫瘍は、ヒト肺がん、ヒト肝臓がん、ヒト大腸がん、ヒト頭頸部がん、ヒト前立腺がん、ヒト乳がん、ヒト卵巣がん、ヒト子宮頸がん、ヒト白血病、ヒトリンパ腫、ヒト皮膚がん、ヒト膵臓がん、ヒト膀胱がん、ヒト食道がん、ヒト胃がん、ヒト男性生殖器がん、ヒト甲状腺がん、ヒト骨がん、又はヒト黒色腫、ヒト口腔がんである請求項8に記載の使用。
- 前記腫瘍の細胞は、ヒト結腸がん細胞HT29、ヒト非小細胞肺がん細胞A549、ヒト肝臓がん細胞SMMC7721、ヒト乳がん細胞MCF−7、ヒト卵巣がん細胞SKOV3、ヒト食道がん細胞ECA109、ヒト前立腺がん細胞DU145、ヒト子宮頸がん細胞Hela、ヒト黒色腫細胞A375、ヒト口腔類表皮がん細胞KB、ヒト胃がん細胞HGC27、ヒト甲状腺がん細胞SW579、ヒト膀胱がん細胞5637、ヒト膵臓がん細胞Panc−1、ヒト大細胞肺がん細胞H460、ヒト形質細胞白血病細胞H929、ヒト肝臓がん細胞HepG2、ヒト単球性白血病THP−1であることを特徴とする請求項9に記載の使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810174599.9 | 2018-03-02 | ||
CN201810174599.9A CN110218230B (zh) | 2018-03-02 | 2018-03-02 | 维生素c偶联铂配合物、其中间体、其制备方法、药物组合物及用途 |
PCT/CN2019/084838 WO2019166033A2 (zh) | 2018-03-02 | 2019-04-28 | 维生素c偶联铂配合物、其中间体、其制备方法、药物组合物及用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2021515046A true JP2021515046A (ja) | 2021-06-17 |
JP7048769B2 JP7048769B2 (ja) | 2022-04-05 |
Family
ID=67805629
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020568589A Active JP7048769B2 (ja) | 2018-03-02 | 2019-04-28 | ビタミンcカップリング白金錯体、その中間体、その製造方法、医薬組成物及び使用 |
Country Status (4)
Country | Link |
---|---|
JP (1) | JP7048769B2 (ja) |
KR (1) | KR102482090B1 (ja) |
CN (1) | CN110218230B (ja) |
WO (1) | WO2019166033A2 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114940692B (zh) * | 2022-06-17 | 2023-12-01 | 重庆文理学院 | 一类具有抗肺癌作用的化合物及其制备方法和应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6013795A (ja) * | 1983-06-20 | 1985-01-24 | リサ−チ・コ−ポレイシヨン | ジアミノシクロヘキサン白金錯体 |
CN102716145A (zh) * | 2012-06-20 | 2012-10-10 | 天津谷堆生物医药科技有限公司 | 含糖铂配合物在制备防治肿瘤药物的用途 |
US20140349955A1 (en) * | 2011-06-24 | 2014-11-27 | Gudui Bipharma Technology Inc. | Use of fluorine-containing water soluble platinum complex in preparing drugs for prevention and treatment of cancers |
US20150051387A1 (en) * | 2011-06-24 | 2015-02-19 | Gudui Biopharma Technology Inc. | Water soluble platinum complexes for tumor treatment and process of preparing same |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS58124797A (ja) * | 1982-01-20 | 1983-07-25 | Shionogi & Co Ltd | 新規1,2−シクロヘキサンジアミン白金錯体 |
CN1203080C (zh) * | 2003-06-19 | 2005-05-25 | 南京大学 | 樟脑酸根为配体的抗肿瘤铂(ⅱ)配合物 |
CN1274674C (zh) * | 2004-04-30 | 2006-09-13 | 南开大学 | 丙二硒桥联双环糊精铂配合物的用途 |
WO2007095627A2 (en) * | 2006-02-15 | 2007-08-23 | Zymes, Llc | Pqs: a new hydrotrope for solubilizing lipophilic compounds in water |
CN100413874C (zh) * | 2006-03-17 | 2008-08-27 | 昆明贵研药业有限公司 | 新型水溶性Pt(Ⅱ)抗癌配合物及其制备方法 |
CN101891769B (zh) * | 2010-06-18 | 2013-01-16 | 河北大学 | 抗肿瘤药物铂配合物 |
CN102276674A (zh) * | 2011-06-24 | 2011-12-14 | 天津大学 | 用于肿瘤靶向治疗的含半乳糖铂配合物及其制备方法 |
CN105753922B (zh) * | 2016-02-05 | 2019-07-02 | 南开大学 | 用于肿瘤治疗四价铂糖基配合物及其制备方法 |
-
2018
- 2018-03-02 CN CN201810174599.9A patent/CN110218230B/zh active Active
-
2019
- 2019-04-28 KR KR1020207025357A patent/KR102482090B1/ko active IP Right Grant
- 2019-04-28 JP JP2020568589A patent/JP7048769B2/ja active Active
- 2019-04-28 WO PCT/CN2019/084838 patent/WO2019166033A2/zh active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6013795A (ja) * | 1983-06-20 | 1985-01-24 | リサ−チ・コ−ポレイシヨン | ジアミノシクロヘキサン白金錯体 |
US20140349955A1 (en) * | 2011-06-24 | 2014-11-27 | Gudui Bipharma Technology Inc. | Use of fluorine-containing water soluble platinum complex in preparing drugs for prevention and treatment of cancers |
US20150051387A1 (en) * | 2011-06-24 | 2015-02-19 | Gudui Biopharma Technology Inc. | Water soluble platinum complexes for tumor treatment and process of preparing same |
CN102716145A (zh) * | 2012-06-20 | 2012-10-10 | 天津谷堆生物医药科技有限公司 | 含糖铂配合物在制备防治肿瘤药物的用途 |
Non-Patent Citations (1)
Title |
---|
HANESSIAN, S. ET AL.: "Design and synthesis of a cephalosporin-carboplatinum prodrug activatable by a β-lactamase", CAN. J. CHEM., vol. 71, JPN6021032208, 1993, pages 896 - 906, XP002270046, ISSN: 0004576787 * |
Also Published As
Publication number | Publication date |
---|---|
WO2019166033A3 (zh) | 2019-10-31 |
CN110218230A (zh) | 2019-09-10 |
KR20200140248A (ko) | 2020-12-15 |
WO2019166033A2 (zh) | 2019-09-06 |
CN110218230B (zh) | 2022-06-28 |
KR102482090B1 (ko) | 2022-12-27 |
JP7048769B2 (ja) | 2022-04-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2017148193A1 (zh) | 一类含有生物活性基团的四价铂配合物及其制备方法 | |
ES2903416T3 (es) | Método de preparación de un inhibidor de tirosina quinasa y de un derivado del mismo | |
CN102702293B (zh) | 用于肿瘤治疗的水溶性铂配合物及其制备方法 | |
CN102718824B (zh) | 用于肿瘤治疗的含氟水溶性铂配合物及其制备方法 | |
CN107955042B (zh) | 具有抗癌活性的铂类配合物、制备方法及应用 | |
RU2039064C1 (ru) | Четырехкоординационные комплексы двухвалентной платины | |
JP7048769B2 (ja) | ビタミンcカップリング白金錯体、その中間体、その製造方法、医薬組成物及び使用 | |
CN114380864A (zh) | 一种双氢青蒿素衍生物、制备方法、药物组合物和其在制备抗肿瘤药物中的应用 | |
KR102640022B1 (ko) | 시클로부탄 디카르복실산 백금 착체, 그의 중간체, 그의 제조방법, 의약 조성물 및 사용 | |
CN107286220B (zh) | 1,2,4-三氮唑偶联的二氢杨梅素衍生物及其制备方法和应用 | |
JP7096559B2 (ja) | トリプトリド誘導体およびその製造方法と使用 | |
CN107827934B (zh) | 具有抗癌活性的四价铂配合物、制备方法及应用 | |
KR20180055135A (ko) | 벤조사이아졸 유도체가 결합된 리간드-금속 복합체 및 이의 제조 방법 | |
RU2666898C1 (ru) | Комплексы платины (iv) с повышенной противораковой эффективностью | |
CN110981882A (zh) | 一类白屈菜碱一氧化氮供体衍生物及其制备方法和用途 | |
CN109705187B (zh) | 一种雷公藤红素衍生物及其制备方法与应用 | |
CN106608892B (zh) | 含氟水溶性铂配合物及制备方法及用途 | |
CN110396086B (zh) | No供体类化合物、组合物、制备方法和及其应用 | |
JPH01117885A (ja) | 新規ボドフィロトキシン誘導体及びその製造法 | |
CN104788498B (zh) | 一种以手性双环二胺为载体配体的铂(ii)配合物及其制备方法和应用 | |
CN106608898B (zh) | 含脱氧葡萄糖水溶性铂配合物及制备方法及用途 | |
CN111763236B (zh) | 一类沙蟾毒精氨基甲酸酯衍生物及其应用 | |
US9120816B2 (en) | Oxanorbornadiene derivatives and their anticancer activities | |
US11661434B2 (en) | Phosphate of platinum compound and preparation method therefor | |
WO2015180549A1 (zh) | L-丙氨酸-(14-冬凌草甲素)酯三氟乙酸盐的i型结晶及制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200914 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210824 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211124 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20220315 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20220324 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7048769 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |